Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India

Introduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 replacing the injectabl...

Description complète

Détails bibliographiques

Auteurs principaux:	Hindol Mondal, Manasi Basu Banerjee, Abheek Das, Somnath Maity
Format:	Artigo
Langue:	Inglês
Publié:	Wolters Kluwer Medknow Publications 2025-07-01
Collection:	Journal of Advanced Lung Health
Sujets:	adverse events bedaquiline multidrug-resistant/rifampicin-resistant tuberculosis
Accès en ligne:	https://journals.lww.com/10.4103/jalh.jalh_64_24
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!